The results of our hypothesis-generated study suggest a unidirectional inhibitory effect from mutant p53 upon ER signaling, which may preclude a selective advantage acquired ESR1 mutations in a tumor with mutant p53 as the founder mutation. This evidence concerns the gene ESR1 and neoplasm.